Investigation of the Enhancement of the Response to Hepatitis B Vaccine by Lenalidomide (RevlimidTM, CC-5013) in Plasma Cell Dyscrasias
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Lenalidomide (Primary) ; Hepatitis B vaccine
- Indications Hepatitis B
- Focus Pharmacodynamics
- Sponsors Boston VA Research Institute
- 10 Apr 2016 Status changed from active, no longer recruiting to completed.
- 24 Feb 2014 New trial record